Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer
Primary Sponsor
ANZUP
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre
Accrual Target
800
Final Accrual
802
Closing Date of Accrual
30 June 2018
Trial Contact
enzarad.study@sydney.edu.au
Related Post
16 July, 2026
TROG 08.03 RAVES sub-study sheds light on quality of life after post-prostatectomy radiotherapy
LATEST NEWS: 16 July 2026 Secondary analysis of data
15 July, 2026
TROG 18.01 NINJA prostate cancer trial completes recruitment
LATEST NEWS: 15 July 2026 The TROG 18.01 NINJA